Sign in Subscribe
Health care industry

Fair-Market Value Compensation Rates for Cardiology Key Opinion Leaders in Australia

Strategic Insights

— 1 min read

The report "KOL Compensation Australia Cardiology" provides fair-market value (FMV) compensation rates for Australian Key Opinion Leaders (KOLs) in cardiology, offering a comprehensive guide to industry standards. Amidst growing scrutiny of payments made to physicians and thought leaders, companies have been adjusting their rates to align with industry benchmarks. Establishing fair-market value compensation rates is crucial to reducing external perceptions of improper inducement, limiting regulatory risks, and providing a reference for negotiations with thought leaders and healthcare providers.

Key Takeaways:

  • The report presents FMV compensation rates for Australian KOLs in cardiology, categorized by percentile, with averages for six activities and non-specific activities, for four levels of thought leader influences (rare, international, national, and local).
  • The data is built from industry compensation paid to healthcare practitioners (HCPs) and thought leaders (KOLs), providing a reliable methodology for collecting market-based rate data.
  • Companies can use the report to reduce regulatory and compliance risks, provide an independent reference for negotiations, and support the development of fee schedules aligned with market conditions.
  • The data included in the report is an aggregate of collected data, with individual contributions anonymized to protect contributor identities.
  • Pharmaceutical organizations can benefit from engaging thought leaders early, with 63% waiting until phases 2 and 3 to start exchanging with KOLs, likely hindering optimal results.
  • The report covers key topics, including research methodology, definitions, therapeutic area, thought leader levels, salary data, and market rates, among others.

Statistics:

  • Less than 25% of pharmaceutical organizations begin working with KOLs during or before the clinical phase.
  • 63% of pharmaceutical organizations wait until phases 2 and 3 to start exchanging with KOLs.
  • The data is built from industry compensation to HCPs and KOLs, providing reliable market-based rate information.

Sources:

  • ResearchAndMarkets.com
  • https://www.researchandmarkets.com/r/hr0ec8
  • BusinessWire: https://www.businesswire.com/news/home/20251103075219/en/

Read more